GoodRx (Nasdaq: GDRX), the leading platform for medication savings in the U.S., announced that via a collaboration with Novo Nordisk, all strengths of Ozempic® (semaglutide) and Wegovy® (semaglutide) pens are available to eligible self-paying patients for $499-per-month through GoodRx, effective today.
PICO IV, the pioneers behind the world's first sterile CBD emulsion, have announced a strategic partnership with Liquivida®, a national leader in IV therapy and wellness. This partnership marks an exciting turn for both companies as they continue to innovate in IV hydration while upholding the highest standards of safety and education.
Switch Bioworks, a biotechnology company developing low-cost and sustainable fertilizers, announced the addition of two senior leaders to its executive team and a move into a new, dedicated corporate headquarters and R&D facility in San Carlos, California.
Daewoong Pharmaceutical (Co-CEOs Seong-Soo Park and Chang-Jae Lee) and Daewoong Therapeutics (CEO Bok-Ki Kang) announced that their proprietary semaglutide microneedle patch achieved more than 80%relative bioavailability compared to the injectable formulation in a pilot human pharmacokinetic study.
Jazz Pharmaceuticals plc announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Modeyso™ (dordaviprone) for the treatment of adult and pediatric patients 1 year of age and older with diffuse midline glioma harboring an H3 K27M mutation with progressive disease following prior therapy.1 Continued approval for this indication may be contingent upon verification and description of clinical benefit in the Phase 3 ACTION confirmatory trial.
Asahi Kasei Life Science, a division of diversified global manufacturer Asahi Kasei, announced plans to construct a new spinning plant for its Planova™ virus removal filters in Nobeoka City, Miyazaki, Japan. The new facility will be the company’s fourth spinning plant for hollow-fiber cellulose membrane filters.
Seegene Inc., a global leader in molecular diagnostics, announced that it will unveil its fully automated PCR testing system, CURECA™, and its data analytics platform, STAgora™, at ADLM 2025 (Association for Diagnostics & Laboratory Medicine), the world's largest diagnostics conference, taking place in Chicago from July 28 to 31. With the introduction of these new technologies, Seegene declares a transformative shift in the global diagnostics paradigm.
Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or affiliated companies, "Sun Pharma") today announced LEQSELVI™ (deuruxolitinib) 8 mg tablets is now available to healthcare providers and people living with severe alopecia areata in the U.S. LEQSELVI is indicated for the treatment of adults with severe alopecia areata.
Niagen Bioscience, Inc. the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, announced the inaugural hotel debut of Tru Niagen® as an in-room amenity at the Equinox Hotel New York, and Niagen IV, now available at the hotel’s spa through NutriDrip
A new independent study has revalidated the use of C15:0 to reverse core components of a newly discovered nutritional C15:0 deficiency syndrome, called Cellular Fragility Syndrome, which may be impacting as many as 1 in 3 people globally.